GlassScriptPhysician profile
Jessiel Rodriguez
NPI 1124698238
$4,239.74
in general payments reported to CMS, 2019-2025
32 companies · $855 in 2025
The $855 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.24 · 2022: $1,287 · 2023: $943 · 2024: $1,116 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,913.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,370.73 | 2022-2024 | Axonics |
| Sumitomo Pharma America, INC. | $583.09 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $560.90 | 2022-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $277.25 | 2023-2024 | |
| 180 Medical, INC. | $252.10 | 2021-2025 | Gentlecath, Gentlecath Glide |
| Lilly USA, LLC | $151.20 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $143.89 | 2025 | |
| Urovant Sciences INC | $126.86 | 2022 | |
| Exact Sciences Corporation | $105.84 | 2023-2024 | Cologuard Collection Kit |
| Tolmar, INC. | $63.80 | 2023-2025 | Eligard |
| Coloplast Corp | $63.10 | 2023-2025 | Speedicath |
| Janssen Pharmaceuticals, INC | $51.85 | 2022-2023 | Xarelto |
| Amgen INC. | $44.11 | 2022-2024 | Repatha |
| Alnylam Pharmaceuticals INC. | $44.06 | 2023 | Onpattro |
| Abbvie INC. | $42.78 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $40.16 | 2022-2023 | Prolaris |
| Bluewind Medical | $38.28 | 2025 | Revi |
| Merck Sharp & Dohme LLC | $28.94 | 2022 | |
| Viiv Healthcare Company | $26.01 | 2025 | Apretude |
| Eisai INC. | $22.35 | 2022 | |
| Smith+Nephew, INC. | $21.40 | 2021 | |
| Dexcom, INC. | $19.36 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $19.09 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $18.34 | 2022 | |
| Halozyme INC | $17.87 | 2023 | |
| Telix Pharmaceuticals | $16.98 | 2023 | Illuccix |
| Glaxosmithkline, LLC. | $16.66 | 2022 | |
| Redhill Biopharma INC. | $15.53 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.40 | 2022 | |
| Medtronic, INC. | $14.11 | 2024 | Synchromedii |
| Bayer Healthcare Pharmaceuticals INC. | $13.87 | 2022 | |
| Angiodynamics, INC. | $13.83 | 2023 | Nanoknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessiel Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.